Cell therapy · developed by Vericel
Ixmyelocel-T is a cell therapy given as intramuscular injections into the affected leg. It is being studied in critical limb ischemia, a severe circulatory condition of the legs.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01483898 | Phase 3 | Critical Limb Ischemia | Completed | VCEL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Critical Limb Ischemia
Updated Nov 1, 2026. Something wrong or missing? Report it on the VCEL page.
See VCEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VCEL catalysts and pipeline →